昆药集团
(600422)
| 流通市值：66.24亿 | | | 总市值：66.24亿 |
| 流通股本：7.57亿 | | | 总股本：7.57亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,722,378,839.14 | 1,643,045,313.73 | 836,158,258.4 | 6,575,214,133.55 |
| 营业收入 | 2,722,378,839.14 | 1,643,045,313.73 | 836,158,258.4 | 6,575,214,133.55 |
| 二、营业总成本 | 3,040,478,562.5 | 1,961,200,668.75 | 1,005,316,275.73 | 6,335,560,770.88 |
| 营业成本 | 2,133,994,430.11 | 1,326,466,364.74 | 647,460,348.24 | 4,042,284,632.19 |
| 税金及附加 | 22,633,730.36 | 15,145,330.53 | 6,914,899.7 | 60,455,242.15 |
| 销售费用 | 565,087,967.98 | 398,191,117.61 | 241,421,364.92 | 1,708,462,496.46 |
| 管理费用 | 243,711,204.95 | 169,524,997.22 | 83,628,103.79 | 378,558,162.68 |
| 研发费用 | 47,195,668.27 | 31,307,095.95 | 15,270,107.62 | 102,548,170.75 |
| 财务费用 | 27,855,560.83 | 20,565,762.7 | 10,621,451.46 | 43,252,066.65 |
| 其中:利息费用 | 23,750,172.89 | 17,307,552.78 | 8,663,197.43 | 50,588,546.01 |
| 其中:利息收入 | 3,563,740.78 | 2,068,669.39 | 701,643.89 | 10,000,393.17 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 30,779,157.04 | 8,294.49 | 40,566,944.52 | 108,913,808.46 |
| 加:投资收益 | 4,988,406.49 | -6,373,078.66 | 19,627,546.81 | 62,011,166.44 |
| 资产处置收益 | 1,124,430.22 | 1,175,575.72 | 438,657.93 | 673,035.91 |
| 资产减值损失(新) | -94,536,891.64 | -45,417,852.81 | -12,774,711.76 | -31,589,763.74 |
| 信用减值损失(新) | -90,771,460.85 | -69,876,375.85 | -17,747,958.82 | -23,459,591.86 |
| 其他收益 | 59,160,411.71 | 47,786,894.78 | 5,046,325.73 | 92,305,932.18 |
| 四、营业利润 | -407,355,670.39 | -390,851,897.35 | -134,001,212.92 | 448,507,950.06 |
| 加:营业外收入 | 2,918,422.34 | 2,542,845.39 | 291,931.28 | 26,279,181.57 |
| 减:营业外支出 | 8,758,381.21 | 7,367,779.22 | 4,581,606.17 | 1,229,292.96 |
| 五、利润总额 | -413,195,629.26 | -395,676,831.18 | -138,290,887.81 | 473,557,838.67 |
| 减:所得税费用 | -49,743,914.51 | -25,982,117.46 | 6,556,763.98 | 54,504,976.99 |
| 六、净利润 | -363,451,714.75 | -369,694,713.72 | -144,847,651.79 | 419,052,861.68 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -363,451,714.75 | -369,694,713.72 | -144,847,651.79 | 419,052,861.68 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -365,929,467.21 | -363,947,613.06 | -141,783,891.37 | 349,940,750.73 |
| 少数股东损益 | 2,477,752.46 | -5,747,100.66 | -3,063,760.42 | 69,112,110.95 |
| 扣除非经常损益后的净利润 | -436,454,669.7 | -390,295,088.73 | -190,227,125.75 | 107,110,148.34 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.48 | -0.48 | -0.19 | 0.46 |
| (二)稀释每股收益 | -0.48 | -0.48 | -0.19 | 0.46 |
| 八、其他综合收益 | -1,237,975.28 | -1,485,007.07 | -1,449,310.54 | -12,037,693.62 |
| 归属于母公司股东的其他综合收益 | -1,196,801.29 | -1,426,425.88 | -1,368,890.02 | -12,213,098.61 |
| 九、综合收益总额 | -364,689,690.03 | -371,179,720.79 | -146,296,962.33 | 407,015,168.06 |
| 归属于母公司股东的综合收益总额 | -367,126,268.5 | -365,374,038.94 | -143,152,781.39 | 337,727,652.12 |
| 归属于少数股东的综合收益总额 | 2,436,578.47 | -5,805,681.85 | -3,144,180.94 | 69,287,515.94 |
| 公告日期 | 2026-10-24 | 2026-08-22 | 2026-04-25 | 2026-03-20 |
| 审计意见(境内) | | | | 标准无保留意见 |